Well said, Jay! As an aside, before entering into the

New Post Public Reply Private Reply Replies (1) Message Board
patientgal jayreese #951

Well said, Jay!

As an aside, before entering into the ever-changing world of pharma & the regulations attached, I was a business owner that dealt primarily with the exportation of goods. Since I was, in the grand scheme of things, a small fish in a small bowl filled with big mouths that had been in the business a long time, I was always waiting so much longer than the rest for government approvals as it pertained to customs, regulations, etc., etc.. Quite simply, had I had the financial resources or the connections, things would have moved a lot faster  and simpler for me.

The same can be said for BMSN in that the science they are working to introduce is laden with  complexities beyond biology--because they do not have the money or connections BP have, their job to enter into a market that has been ruled by a few for so long is that much harder.

Governmental red-tape sucks.

Have no doubt though, I KNOW they are on radars. Personally, I think Koos is a bloody genius.

The ugly face of Cancer has reared itself close to me on more than one occasion. Though I would like to retire by way of my financial investment in this company, I would love more to see what they are doing come to fruition for the sake of those that have been awaiting relief.

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Ipsen's Kayfanda® Receives EU Approval for Alagille Syndrome Treatment

Updated Category News Views 67

Kayfanda® Receives Approval for Treatment in the EU Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 144

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
AeroPress Launches Premium Coffee Press with Elegant Design

Updated Category News Views 332

AeroPress introduced its Premium coffee press back in 2024, and you can bet the market was watching closely. With a retail price of $149.95, this isn’t just another brewing tool; it’s a statement piece designed for those who take their morning ritual seriously. Traders buzzed about how this could impact sales in a saturated market where every new gadget fights for...

Continue Reading
Investigation Update: Walgreens Boots Alliance Class Action Lawsuit

Updated Category News Views 327

Overview of the Walgreens Boots Alliance Class Action Levi & Korsinsky, LLP has raised awareness among investors regarding a class action securities lawsuit involving Walgreens Boots Alliance, Inc. This company, known for its extensive pharmaceutical and retail operations, is currently facing legal challenges that could significantly impact its investors. Class Definition...

Continue Reading
Savillex Strengthens Market Position with New Acquisition

Updated Category News Views 38

Savillex Acquires Optimum Processing to Enhance Offerings Thompson Street Capital Partners (TSCP) is proud to announce that its portfolio company, Savillex, has completed the acquisition of Optimum Processing, Inc. This strategic move is expected to elevate Savillex's position in the marketplace by combining its innovative fluid handling solutions with Optimum...

Continue Reading